Benefit Medical Methods, Inc. (MMSI) Q2 2026 Earnings Name Transcript
Benefit Medical Methods, Inc. (MMSI) Q2 2026 Earnings Name July 30, 2026 4:30 PM EDT
Firm Members
Martha Aronson – President, CEO & Director
Brian Lloyd – Chief Authorized Officer & Company Secretary
Raul Parra – CFO & Treasurer
Convention Name Members
Jason Bednar – Piper Sandler & Co., Analysis Division
Lilia-Celine Lozada – JPMorgan Chase & Co, Analysis Division
Lei Huang – Wells Fargo Securities, LLC, Analysis Division
Aidan Lahey – BofA Securities, Analysis Division
Michael Matson – Needham & Firm, LLC, Analysis Division
Michael Petusky – Barrington Analysis Associates, Inc., Analysis Division
Sam Eiber – BTIG, LLC, Analysis Division
David Rescott – Robert W. Baird & Co. Included, Analysis Division
Zachary Day – Canaccord Genuity Corp., Analysis Division
James Sidoti – Sidoti & Firm, LLC
Presentation
Operator
Welcome to Benefit Medical Methods’ Second Quarter 2026 Earnings Convention Name. [Operator Instructions] Please word that this convention name is being recorded and that the recording will probably be out there on the corporate’s web site for replay shortly.
I’d now like to show the decision over to Martha Aronson, Benefit Medical Methods’ President and Chief Govt Officer.
Martha Aronson
President, CEO & Director
Thanks, operator, and welcome, everybody. I’m joined on the decision immediately by Raul Parra, our Chief Monetary Officer and Treasurer; and Brian Lloyd, our Chief Authorized Officer and Company Secretary.
Brian, would you thoughts taking us by way of the secure harbor statements, please?
Brian Lloyd
Chief Authorized Officer & Company Secretary
Thanks, Martha. This presentation incorporates forward-looking statements that obtain secure harbor safety beneath federal securities legal guidelines. Though we imagine these forward-looking statements are primarily based upon affordable assumptions, they’re topic to dangers and uncertainties. The belief of any of those dangers or uncertainties in addition to extraordinary occasions or transactions impacting our firm may trigger precise outcomes to vary materially from the expectations and projections expressed or implied by our forward-looking
